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Residue number 17 in transmembrane segment VI has been shown to be crucial for the binding of agonists in G-protein-coupled receptors for the 
monoamines. In many peptide receptors a histidyl residue has been conserved at this position. We find that replacement of Hisvi*17 in the NK-1 
receptor with either glutamine, phenylalanine, or alanine has no apparent effect on the binding of the natural peptide ligand substance P or on 
the agonist induced increase in inositolphosphate turnover. However, the binding of certain non-peptide antagonists was impaired; for example, 
replacement of Hisw-” with alanine decreased the affinity for FK888 and RP67,580 5- to 12-fold, respectively. A glutamine side chain was a good 
substitute for the imidazole in the binding of a.ll non-peptide antagonists. It is concluded that the conserved Hisv’-‘7 in the NK-1 receptor is involved 
in the binding of certain non-peptide antagonists, but is not important for the action of the natural peptide agonist, substance P
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1. INTRODUCTION 
In the large superfamily of G-protein-coupled recep- 
tors, ligand binding sites for monoamine transmitters 
have been characterized in rather great detail. Through 
a combination of molecular biology and medicinal 
chemistry an ionic interaction between the amine func- 
tion of the monoamines and the Aspartate residue lo- 
cated in position 8 in transmembrane segment III 
(As~“‘-~ in TM-III) has been shown to be crucial for 
high affinity binding of the ligand [l]. The activation of 
the receptor is apparently obtained through the interac- 
tion of the catechol ring with residues in TM-V and -VI. 
The catechol ring appears to be correctly orientated 
through hydrogen-bonding with two serine residues in 
TM-V, Servd and Servq7, thus providing the appropriate 
interaction between the aromatic ring and the hydro- 
phobic residues in TM-VI; in the case of the /3-adrener- 
gic receptor, this would especially involve Phev’-17 [2,3]. 
Molecular models have been developed in which resi- 
dues located at the corresponding positions in other 
receptors are imagined to be involved in the binding of 
many other classes of ligands [4,5]. In the case of recep- 
tors for serotonin (SHT), it has recently been demon- 
strated by mutagenesis that Phevi-i7 is important for the 
binding of the agonists, and of certain antagonists 
which are structurally similar to the agonists [6]. Based 
on molecular modeling it has been speculated that the 
corresponding residue, HisV”17, in the adenosine recep- 
tors, could be involved in the binding of the carbohy- 
drate moiety of the adenosine agonist [7]. As shown in 
Fig. 1, in most peptide receptors residue 
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number 17 in 
TM-VI is either a histidyl residue or another polar res- 
idue, that might similarly be involved in the binding of 
the polar peptide ligands. 
Substance P is an important neuropeptide, which is 
believed to play an important role in afferent transmis- 
sion of sensory stimuli and for the neurogenic ontribu- 
tion to especially cronic inflammatory processes [8-IO]. 
A series of non-peptide antagonists have been devel- 
oped, which specifically and with high afhnity block the 
substance P receptor, NK-1 [lo]. These compounds, 
which do not structurally resemble substance P, have 
been discovered mainly through screening of chemical 
files. Recently, the binding sites for a series of non- 
peptide NK-I antagonists have been located to a dis- 
continuous epitope around the outer portion of TM-V 
and -VI [I 1,121 (and Gether et al. submitted for publica- 
tion). Here, we study the importance of Hisvi-17, which 
has been suggested to be part of the binding site for 
substance P [13], by replacing it with, respectively, ala- 
nine, glutamine or phenylalanine. Surprisingly, this his- 
tidy1 residue appears to be of no importance for agonist 
binding or receptor activation, while it is clearly in- 
volved in the binding of the non-peptide antagonists. 
2. MATERIALS AND METHODS 
2.1. Peptide and non-peptide ligands 
Substance P was purchased from Peninsula (St. Helens, Merseyside, 
UK). The following non-peptide compounds were used: CP 96,345, 
(2S,3S)-c&2-diphenyhnethyl)-~(2 -methoxyphenyl)methyl]-l-azabi- 
cyclo[2.2.2]octan-3-amine supplied by John A. Lowe III, Pfrxer, 
Groton, CT [14]; SR 140,133, (S) I-{2-[3-(3,4dichlorophenyl)-1-(3- 
isopropoxyphenylacetyl)piperidin-3-yl]ethyl}-4-phenyl-l-azabicyclo- 
[2.2.2]octan, chloride supplied by Xavier Emonds-Ah, Sanofi 
Recherche, F-34184 Montpellier, France [15]; FK888, @-[(4R)4 
hydroxy-l-[(1-methyl-lH-indole-3-yl)-~-propyl]-N-methyl-N-(phenyl- 
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methyl)-3-(2-naphthyl)-t,-alaninamide supplied by Takashi Fujii, Fu- 
jisawa Pharmaceutical Co., Osaka, Japan [16]; and RP67,580, 2-[l- 
imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl4~rhydroisoindolo- 
ne (3aR,7aR) supplied by Laurant Pradier, Rhone-Poulenc 
Rorer, Vitry sur Seine, France [17]. 
2.2. Site-directed mutagenesis 
Substitution of His\“-“, corresponding to Hisz5, in the human NK-1 
receptor (cDNA generously supplied by Drs. Norma and Craig Ger- 
ard) with Ala, Gln, or Phe was performed by extension of mutated 
internal primers using T4 DNA polymerase followed by selective am- 
plification of the mutated DNA by the polymerase chain reaction 
(PCR) according to methods described [18]. Briefly, an initial synthesis 
reaction was carried out with T4 polymerase and T4 DNA ligase after 
the annealing of both a sense ohgonucleotide containing the desired 
mutation and an upstream oligonucleotide with a non-homologous 5
add-on sequence to a single-stranded Ml3 template of the human 
NK-1 receptor cDNA. The mutated DNA strand was thereafter selec- 
tively amplified by PfuPolymerase-mediated PCR using a sense primer 
corresponding to the non-homologous 5’ add-on sequence of the up- 
stream primer and a non-sense primer located downstream of the 
mutation site. The cDNA encoding the wild-type or the mutated 
receptors were cloned into the pTEJ-8 expression vector [19]. The 
structure of the recombinant genes was verified by restriction endonu- 
clease mapping and by DNA sequence analysis. 
2.3. Transfections and tissue culture 
The expression plasmids containing the cDNAs encoding the wild- 
type NK-1 and the mutant receptors were transiently transfected into 
COS-7 cells by the calcium phosphate precipitation method according 
to previously reported methods [11,19]. 
2.4. Binding experiments 
Monoiodinated ‘251-Bolton Hunter-labeled substance P ([‘*‘I]BH- 
SP) was prepared and purified by HPLC as described in detail previ- 
ously [20]. The transfected COS-7 cells were transferred to 12-well 
culture plates, 0.1-0.6 x 10’ cells/well, 1 day after transfection and 
24 h before performing the binding experiments, as described. The 
number of cells per well was adjusted according to the expression 
efficiency of the individual plasmid aiming at 5-10% binding of the 
added radioligand in the competition binding experiments. Binding 
experiments were performed for 3 h at 4’C with 50 pM [iZ51]BH-SP 
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plus variable amounts of unlabeled peptide or non-peptide compound 
present in 0.5 ml of a 50 mM Tris-HCl, pH 7.4, containing 150 mM 
NaCl, 5 mM MnCl,, and 0.1% (w/v) bovine serum albumin (Sigma) 
supplemented with 100 &ml bacitracin (Sigma). All determinations 
were performed in triplicate and the non-spechic binding was deter- 
mined as the binding in the presence of 1 PM substance P. The specific 
binding constituted more than 80% of the total binding. The binding 
data were analyzed and IC, values determined by computerized non- 
linear regression analysis using InPlot (GraphPad Software, San 
Diego, CA). Kn, B_, and KI values for binding of radiolabeled sub- 
stance. P to the different receptors were estimated from competition 
binding experiments using different concentrations of the unlabeled 
peptide as indicated in the figures [20]. 
2.5. Inositol phosphate turnover 
COS cells were seeded in 12-well culture plates at a density of 5 x lo5 
cells/well and incubated with [31-Ilmyo-inositol (2.5 #Zi/well) (PT6-271 
from Amersham, Little Chalfont, UK) for 24 h in inositol-free Dul- 
becco’s 1885 medium supplemented with 10% fetal calf serum, 2 mM 
glutamine and 0.1 mg/ml gentamicin. The cells were washed twice in 
assay buffer (20 mM HEPES, pH 7.4, containing 140 mM NaCl, 5 mM 
KCl, 1 mM MgSO,, 1mM CaC12, 10 mM glucose, and 0.05% BSA) 
and preincubated for 30 min at 37°C in 0.5 ml assay buffer containing 
10 mM LiCl before addition of peptide agonists. The antagonists were 
added 5 min prior to the addition of peptide agonist. After 20 min of 
incubation at 37°C the cells were extracted by addition of 0.5 ml 
ice-cold 10% perchloric acid followed by incubation on ice for 30 min. 
The resulting supematants were neutralized and the generated 
[‘H]inositol phosphates were separated from [31-Qnositol using of a 
slurry of Bio-Rad AG 1-X8 anion-exchange resins, 10&200 mesh, 
formate form (Bio-Rad Laboratories, Hercules, CA) according to 
principles previously described [21]. 
3. RESULTS 
The binding of substance P was unaffected by the 
substitution of HisW-” in the human NK-1 receptor 
with either Ala, Gln, or Phe, as reflected in unaltered 
competition binding experiments using radiolabeled 
substance P (Fig. 2). Furthermore, substance P stimu- 
Fig. 1. Structure of transmembrane segment VI (TM-VI) of the human NK-1 receptor. (Right panel) The position of I-Bs”‘-‘~ (HASH’) in the 
presumably helical structure of TM-VI of the human NK-1 receptor. (Left panel) Alignment of the amino acid sequences of a representative 
adrenergic, serotinergic and an adenosine receptor plus a series of peptide receptors. The numbering of the residues in the helii is according to 
the nomenclature of Hibert et al. [4,5]. In all adrenergic and serotinergic receptors residue, VI-17, is a Phe; in all three adenosine receptors it is 
a His; and in most neuropeptide receptors of the rhodopsin family it is either a His residue or another polar residue [26]. 
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Fig. 2. Substance P (SP) binding in His”-I7 substituted human NK-1 receptors. Competition binding experiments using ‘ZSI-labeled substance P
in wild-type hNK-1 receptor (- - -), [Gln vr-17]hNK-l (o), [AlaV’~‘7]hNK-l (w), or [Phe”“r7]hNK-1 (A) expressed transiently in COS-7 cells. 
lated inositoiphosphate turnover to a similar degree in 
COS-7 cells transiently expressing the wild-type NK-1 
receptor or any of the mutant NK-1 receptors with 
substitutions in position VI-17 (Fig. 3). 
The binding of the non-peptide antagonist, CP96,345, 
has previously been shown not to be affected by chim- 
eric exchanges of non-conserved residues around the 
top of TM-VI in the rat NK-1 receptor [I 11. However, 
when the conserved Hisvi-17 at the top of TM-VI was 
replaced by Ala in the human receptor, an increase in 
the _KI value for CP96,345 from 0.99 to 2.8 nM was 
observed (Fig. 4, lower left panel; Table I). The binding 
of SR140.333 was not affected by this substitution (Fig. 
4, lower right panel). However, in the case of the two 
other non-peptide antagonists, FK888 and RP67,580, 
the His-to-Ala substitution increased their K, values by 
IP turnover 
Fold 
Stimulation 
a factor of 5 and 12, respectively (Fig. 4, upper two 
panels; Table I). Gln was a good substitute for His at 
position VI-17 in the NK-I receptor, with no loss of 
affinity for any of the non-peptide antagonists (Fig. 4; 
Table I), whereas replacement of the His residue with 
Phe yielded inte~ediate results between those observed 
with the Ala- and the Gln-substituted receptors (Table 
I). In all cases, the non-peptide compounds still func- 
tioned as antagonists of the substance P-induced 
increase in inositolphosphate turnover, although the 
response to the antagonists appeared to be slightly less 
in the Glnv1-17-substituted r ceptor (Fig. 3). 
4. DISCUSSION 
Hisv’-*7 in the NK-1 receptor corresponds to Phev1-17 
10 
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Fig. 3. Stimulation and inhibition of inositol phosphate turnover in COS cells expressing wild-type and His”‘~” substituted human NK-I receptors. 
Inositol phosphate turnover was determined as described in the text in COS cells transiently expressing wild-type hNK-1 receptor (n = 3), 
[~a~~17]h~-l (a = 2), [Gln~-‘~hNK-1 (n = Z), or phe vi-‘7]hNK-1 (n = 3). Cells were s~ulat~ with a submit dose of substance P 
(lo-* M) alone (SP) or together with 10s6 M CP96,345 (SP + CP) or 10” M FK888 (SP + FK). Means f S.E.M. are shown. 
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Fig. 4. Non-peptide antagonist binding in His”“” substituted human NK-1 receptors. Competition binding experiments with radiolabeled substance 
P are shown for RP 67,580 (upper left), FK 888 (upper right), CP 96,345 (lower left) and SR 140,333 (lower right), in the wild-type human NK-1 
receptor (- - -) and in the [Ala”““]hNK-l (m) and in the [Glnv’-‘7]hNK-l (0). 
of the monoamine receptors, which has previously been gers [3,6], our observations could indicate that peptides 
shown by mutagenesis to be involved in agonist binding may be able to activate their receptors without reaching 
[3,6]. A His residue or another polar residue has been - at least at this particular point - deep in between the 
conserved at this position in most peptide receptors of transmembrane segments. In fact, all mutagenesis tud- 
the G-protein-coupled class. This imidazol side chain ies in peptide receptors indicate that important interac- 
could be envisioned to function as a hydrogen bond tion points for peptide agonists are located in the super- 
donor and/or acceptor in the binding of the polar pep- ficial parts of the receptors. Thus, it has been known for 
tides like substance P [13]. Nevertheless, in the present a couple of years that the large glycoprotein hormones 
study we find that this His residue apparently is not mainly bind to the large N-terminal segment of their 
involved in the binding of the natural peptide ligand, target receptors [23,24]. Key points of interaction for 
substance P. Recently we have made a similar observa- the relatively small neuropeptides and peptide 
tion in the angiotensin AT, receptor, where a His resi- hormones, like substance P, bombesin, and angiotensin, 
due at position 16 of TM-VI (see Fig. 1) can be replaced have only been located in the extracellular loops, in the 
by Gln, Asn, Phe, or Ala, without loss of binding affin- outermost parts of the transmembrane segments, as well 
ity for angiotensin (Schambye, Hjorth and Schwartz, to as in the N-terminal extracellular extention of their re- 
be published). Since residues in this area are important ceptors [22,25] (and Hjorth, Schambye and Schwartz, to 
for the binding of several small-sized chemical messen- be published). 
Table I 
K, values (nM) for four non-peptide antagonists determined by competition binding experiments with ‘% labeled substance P in COS cells 
transiently expressing the human NK-1 receptor or three mutant forms of this with single substitutions of Hisvie” (HiszsS) 
Substance P 
(Kn) 
RP67,580 FK888 CP96,345 SRl40,333 
hNK-1 0.29 + 0.05 33 + 3 0.72 f 0.07 0.92 + 0.18 0.60 + 0.07 
[Gln”““]hNK-1 0.28 +- 0.05 58 +_ 7 1.72 +_ 0.66 1.53 +- 0.35 0.41+- 0.06 
[Ala”““]hNK-l 0.18 f 0.03 360 f 70 4.2 + 0.2 2.8 + 0.6 0.59 f 0.13 
[Phe”““]hNK- 1 0.36 f 0.03 95 f 7 2.2 AZ 0.5 1.33 + 0.35 0.58 f 0.07 
- 
The KD values for substance P as determined by competition binding experiments are also listed. 
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In contrast to the peptide agonist, the binding of 
several non-peptide antagonists was impaired by the 
substitution of Hisvr*“. This decrease in binding affiity 
was similar in magnitude to that recently described for 
CP96,345 upon substitution of a His residues located at 
the top of TM-V [12]. In the present study, we have not 
made any attempt to identify which part of the 
RP67,580 and FK888 compounds interact with His”“” 
of the NK-1 receptor. However, this problem can be 
addressed by combining a systematic series of com- 
pound analogs with a library of mutant receptors. Re- 
cently, Fong and co-workers in this way found evidence 
for what they interpreted as an amino-aromatic interac- 
tion between the biphenyl group of CP96,345 and the 
other His residue located at the top of TM-V of the 
NK- 1 receptor (His”’ or His”~ [ 121. In that case, a 
glutamine residue was a good substitute with respect o 
the interaction with the non-peptide antagonists, just 
like it was in the present study for His”‘-“. 
Since His”‘-” does not appear to be involved in the 
binding of the natural ligand, the question still remains 
as to why a His residue or a ‘similar’ polar residue has 
been conserved at this particular position in the major- 
ity of peptide receptors of the G-protein-coupled class. 
Possibly, it is simply favorable to have polar residues 
facing inward, i.e. away from the lipids, for stabilization 
of the receptor structure whenever an aromatic residue 
is not needed at this position for agonist binding. 
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